Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

1. Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs

Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs Signal - Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs Dissemination Centre Discover Portal NIHR DC Discover Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs Published on 5 December 2017 A combination of providing clean needles and syringes and offering safer oral (...) therapy, such as methadone, reduced the predicted risk of becoming infected with hepatitis C virus by 71%. Providing both services to people who inject drugs was likely to be cost-effective and has the potential to be cost-saving in some parts of the UK, depending on the size of the local population of people who inject drugs and underlying rates of infection. Current services are estimated to save up to £54 million in costs of treating hepatitis C infection. This is in addition to the savings made

2019 NIHR Dissemination Centre

2. Tenofovir reduces mother-to-child hepatitis B transmission

Tenofovir reduces mother-to-child hepatitis B transmission Signal - Tenofovir reduces mother-to-child hepatitis B transmission Dissemination Centre Discover Portal NIHR DC Discover Tenofovir reduces mother-to-child hepatitis B transmission Published on 25 July 2017 Giving pregnant women with hepatitis B the drug tenofovir reduced the likelihood of passing the infection on to their baby by about 80% and did not have any adverse impact on mother or child. Hepatitis B often doesn't cause any (...) obvious symptoms in adults and typically passes in a few months without treatment, but in children it often persists for years and may cause progressive liver damage with cirrhosis and increased risk of liver cancer. Babies can get the infection from their mother during birth. The findings of this systematic review support current NICE recommendations that pregnant women with active hepatitis B infection are treated in the third trimester using the drug tenofovir and at risk babies immunised after

2019 NIHR Dissemination Centre

3. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. (PubMed)

Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. BACKGROUND: The revolution in hepatitis C virus (HCV) treatment through the development of direct-acting antivirals (DAAs) has generated international interest in the global elimination of the disease as a public health threat. In 2017, this led WHO to establish elimination targets for 2030. We evaluated the impact of public health interventions on the global HCV epidemic and investigated (...) (620 000-670 000) from cirrhosis and liver cancer. A comprehensive package of prevention, screening, and treatment interventions could avert 15·1 million (13·8-16·1) new infections and 1·5 million (1·4-1·6) cirrhosis and liver cancer deaths, corresponding to an 81% (78-82) reduction in incidence and a 61% (60-62) reduction in mortality compared with 2015 baseline. This reaches the WHO HCV incidence reduction target of 80% but is just short of the mortality reduction target of 65%, which could

Full Text available with Trip Pro

2019 Lancet

4. Acetyl-L-carnitine for patients with hepatic encephalopathy. (PubMed)

Acetyl-L-carnitine for patients with hepatic encephalopathy. BACKGROUND: Hepatic encephalopathy is a common and devastating neuropsychiatric complication of acute liver failure or chronic liver disease. Ammonia content in the blood seems to play a role in the development of hepatic encephalopathy. Treatment for hepatic encephalopathy is complex. Acetyl-L-carnitine is a substance that may reduce ammonia toxicity. This review assessed the benefits and harms of acetyl-L-carnitine for patients (...) with hepatic encephalopathy. OBJECTIVES: To assess the benefits and harms of acetyl-L-carnitine for patients with hepatic encephalopathy. SEARCH METHODS: We searched the Cochrane Hepato-Biliary Group Controlled Trials Register, CENTRAL, MEDLINE Ovid, Embase Ovid, LILACS, and Science Citation Index Expanded for randomised clinical trials. We sought additional randomised clinical trials from the World Health Organization Clinical Trials Search Portal and ClinicalTrials.gov. We performed all electronic

2019 Cochrane

5. Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes

Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes - GOV.UK GOV.UK uses cookies to make the site simpler. Search Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes Monitor glucose levels closely in patients with diabetes during direct-acting antiviral therapy for hepatitis C, particularly within the first (...) 3 months of treatment, and modify diabetes medication or doses when necessary. Patients with diabetes may experience symptomatic hypoglycaemia if diabetic treatment is continued at the same dose due to potential for an enhanced hypoglycaemic effect. Published 18 December 2018 From: Therapeutic area: , , Contents Advice for healthcare professionals: rapid reduction in hepatitis C viral load during direct-acting antiviral therapy for hepatitis C may lead to improvements in glucose metabolism

2019 MHRA Drug Safety Update

6. Public health guidance on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance on HIV, hepatitis B and C testing in the EU/EEA SCIENTIFIC AD VICE www.ecdc.europa.eu Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approachECDC SCIENTIFIC ADVICE Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approach ii This guidance was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Andrew J Amato-Gauci and Lara Tavoschi with the support of Helena (...) Kingdom Masoud Dara, World Health Organization (WHO) Regional Office for Europe, Denmark Michael Ninburg, World Hepatitis Alliance, United Kingdom Mika Salminen, National Institute for Health and Welfare, Finland Mojca Maticic, University Medical Centre Ljubljana, Slovenia Nikos Dedes, EATG/Positive Voice, Greece Peter Vickerman, University of Bristol, United Kingdom Philippa Easterbrook, WHO, Switzerland Raj Patel, IUSTI/NHS England, United Kingdom Ruta Kaupe, DIA+LOGS, Latvia Slim Fourati, European

2019 European Centre for Disease Prevention and Control - Public Health Guidance

7. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA Suggested citation: European Centre for Disease Prevention and Control. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach. Stockholm: ECDC; 2018. Stockholm, December 2018 Reproduction is authorised, provided the source is acknowledged. PDF Print ISBN 978-92-9498-291-9 ISBN 978-92-9498-292-6 DOI 10.2900/809892 DOI 10.2900/579896 Catalogue number TQ-06-18-361-EN-N (...) Catalogue number TQ-06-18-361-EN-C © European Centre for Disease Prevention and Control, Stockholm, 2018 Scope and purpose of guidance The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. Figure 1. The case for integrated

2019 European Centre for Disease Prevention and Control - Public Health Guidance

8. Pharmacological interventions for acute hepatitis C infection. (PubMed)

Pharmacological interventions for acute hepatitis C infection. BACKGROUND: Hepatitis C virus (HCV) is a single-stranded RNA (ribonucleic acid) virus that has the potential to cause inflammation of the liver. The traditional definition of acute HCV infection is the first six months following infection with the virus. Another commonly used definition of acute HCV infection is the absence of HCV antibody and subsequent seroconversion (presence of HCV antibody in a person who was previously (...) negative for HCV antibody). Approximately 40% to 95% of people with acute HCV infection develop chronic HCV infection, that is, have persistent HCV RNA in their blood. In 2010, an estimated 160 million people worldwide (2% to 3% of the world's population) had chronic HCV infection. The optimal pharmacological treatment of acute HCV remains controversial. Chronic HCV infection can damage the liver. OBJECTIVES: To assess the comparative benefits and harms of different pharmacological interventions

2018 Cochrane

9. Drugs for hepatitis C: it's time to slash prices!

Drugs for hepatitis C: it's time to slash prices! Prescrire IN ENGLISH - Spotlight ''Drugs for hepatitis C: it's time to slash prices!'', 1 December 2018 {1} {1} {1} | | > > > Drugs for hepatitis C: it's time to slash prices! Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Drugs for hepatitis C: it's time to slash prices! The high prices (...) of hepatitis C drugs are an obstacle to treatment for most of the people around the world who are infected by the virus. When so-called direct-acting antiviral drugs against hepatitis C came onto the market around 2015, some stakeholders hailed them as a means of eradicating this disease. Sofosbuvir (Sovaldi°) was marketed in the United States at the exorbitant price of 1000 dollars per day, reflecting the company's strategy of seeking maximum profits in the richest countries and not eradication

2018 Prescrire

10. Chronic hepatitis B virus infection. (PubMed)

Chronic hepatitis B virus infection. Chronic hepatitis B virus infection is a global public health threat that causes considerable liver-related morbidity and mortality. It is acquired at birth or later via person-to-person transmission. Vaccination effectively prevents infection and chronic hepatitis B virus carriage. In chronically infected patients, an elevated serum hepatitis B virus DNA concentration is the main risk factor for disease progression, although there are other clinical (...) and viral parameters that influence disease outcomes. In addition to liver biochemistry, virological markers, and abdominal ultrasonography, non-invasive assessment of liver fibrosis is emerging as an important assessment modality. Long-term nucleos(t)ide-analogue therapy is safe and well tolerated, achieves potent viral suppression, and reduces the incidence of liver-related complications. However, a need to optimise management remains. Promising novel therapies are at the developmental stage

2018 Lancet

11. Treatment of Adolescents With Chronic Hepatitis C Virus Infection: New Regimen on the Block (PubMed)

Treatment of Adolescents With Chronic Hepatitis C Virus Infection: New Regimen on the Block 30411074 2018 11 14 2471-254X 2 11 2018 Nov Hepatology communications Hepatol Commun Treatment of Adolescents With Chronic Hepatitis C Virus Infection: New Regimen on the Block. 1289-1292 10.1002/hep4.1261 Editorial to Leung et al. "Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4". Indolfi Giuseppe G Pediatric and Liver (...) Unit Meyer Children's University Hospital of Florence Firenze Italy. Ricci Silvia S Pediatric and Liver Unit Meyer Children's University Hospital of Florence Firenze Italy. eng Editorial 2018 11 01 United States Hepatol Commun 101695860 2471-254X 2018 08 31 2018 09 06 2018 11 10 6 0 2018 11 10 6 0 2018 11 10 6 1 epublish 30411074 10.1002/hep4.1261 HEP41261 PMC6211323 Expert Rev Anti Infect Ther. 2015;13(10):1225-35 26202832 Hepatology. 2017 Aug;66(2):371-378 27997679 J Pediatr Gastroenterol Nutr

Full Text available with Trip Pro

2018 Hepatology communications

12. Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V

Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Sofosbuvir (chronische Hepatitis C bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 January 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A17-55 Sofosbuvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-55 Version 1.0 Sofosbuvir (chronic hepatitis C in adolescents) 11 January 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

13. Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Addendum to Commission A17-35

Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Addendum to Commission A17-35 1 Translation of addendum A18-05 Sofosbuvir/Velpatasvir/Voxilaprevir (Chronische Hepatitis C) – Addendum zum Auftrag A17-35 (Version 1.0; Status: 25 January 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 25 January 2018 1.0 Commission: A18-05 Version (...) : Status: IQWiG Reports – Commission No. A18-05 Sofosbuvir/velpatasvir/ voxilaprevir (chronic hepatitis C) – Addendum to Commission A17-35 1 Addendum A18-05 Version 1.0 Sofosbuvir/velpatasvir/voxilaprevir – Addendum to Commission A17-35 25 January 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) – Addendum to Commission A17-35

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

14. Hepatic Encephalopathy in Patients in Lviv (Ukraine) (PubMed)

Hepatic Encephalopathy in Patients in Lviv (Ukraine) 30425951 2018 12 07 2450-131X 6 3 2018 Sep Journal of translational internal medicine J Transl Int Med Hepatic Encephalopathy in Patients in Lviv (Ukraine). 146-151 10.2478/jtim-2018-0021 Hepatic encephalopathy (HE) research has long been impeded by the vague definition of this disabling complication of liver failure. This article provides an overview of the etiology and impact of HE on neuromuscular functions as well as its role (...) in the development of infections and anemia. This was a descriptive study conducted in 36 patients with HE. Close monitoring of these patients was done by checking on several parameters. The etiological distribution: alcohol (67%), hepatitis C virus (HCV; 17%), HCV and alcohol (8%), hepatitis B virus (HBV; 3%), HBV and alcohol (3%), HBV and HCV (6%), and cryptogenic (3%). The laboratory results indicated an elevation of De Ritis level in 69% of cases and in 92% of total bilirubin values. The Halstead-Reitan (H-R

Full Text available with Trip Pro

2018 Journal of translational internal medicine

15. Evaluating Women’s Preferences for Hepatitis C Treatment During Pregnancy (PubMed)

Evaluating Women’s Preferences for Hepatitis C Treatment During Pregnancy 30411077 2018 11 14 2471-254X 2 11 2018 Nov Hepatology communications Hepatol Commun Evaluating Women's Preferences for Hepatitis C Treatment During Pregnancy. 1306-1310 10.1002/hep4.1264 There is a rising prevalence of hepatitis C (HCV) among women of child-bearing age nationally, which prompted a recommendation by national guidelines to screen all women for HCV during pregnancy. Women with HCV during pregnancy (...) of Gastroenterology/Hepatology University of California San Francisco San Francisco CA. Division of Liver Diseases Icahn School of Medicine at Mount Sinai New York NY. Cohen Jennifer J Department of Clinical Pharmacy University of California San Francisco CA. Tien Phyllis C PC Division of Gastroenterology/Hepatology University of California San Francisco San Francisco CA. San Francisco Veterans Affairs Medical Center San Francisco CA. Terrault Norah A NA Division of Gastroenterology/Hepatology University

Full Text available with Trip Pro

2018 Hepatology communications

16. VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B

VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B Haute Autorité de Santé - VAXELIS, vaccin hexavalent contre diphtérie, tétanos, poliomyélite, coqueluche, infections à Haemophilus influenzae type b, hépatite B Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les

2018 Haute Autorite de sante

17. Hepatic Nuclear Receptor Expression Associates with Features of Histology in Pediatric Nonalcoholic Fatty Liver Disease (PubMed)

Hepatic Nuclear Receptor Expression Associates with Features of Histology in Pediatric Nonalcoholic Fatty Liver Disease 30288476 2018 11 14 2471-254X 2 10 2018 Oct Hepatology communications Hepatol Commun Hepatic Nuclear Receptor Expression Associates with Features of Histology in Pediatric Nonalcoholic Fatty Liver Disease. 1213-1226 10.1002/hep4.1232 Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in children and adults. This study examined (...) the relationship between hepatic nuclear receptor (NR) expression and histologic features of NAFLD. Drugs targeting a variety of NRs for nonalcoholic steatohepatitis (NASH) are in clinical trials. Liver messenger RNA was isolated from 40 children (10-19 years) undergoing end-of-treatment biopsy in the Treatment of NAFLD in Children (TONIC) trial. High-throughput quantitative polymerase chain reaction assayed NR messenger RNA. Cluster analysis was used to group 36 NRs, and NR levels were related to histologic

Full Text available with Trip Pro

2018 Hepatology communications

18. Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Trial of Synthetic Preimplantation Factor in Autoimmune Hepatitis (PubMed)

Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Trial of Synthetic Preimplantation Factor in Autoimmune Hepatitis 30411073 2018 11 14 2471-254X 2 10 2018 Oct Hepatology communications Hepatol Commun Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Trial of Synthetic Preimplantation Factor in Autoimmune Hepatitis. 1235-1246 10.1002/hep4.1239 Preimplantation factor (PIF) is an evolutionary conserved peptide secreted by viable embryos which promotes (...) maternal tolerance without immune suppression. Synthetic PIF (sPIF) replicates native peptide activity. The aim of this study was to conduct the first-in-human trial of the safety, tolerability, and pharmacokinetics of sPIF in patients with autoimmune hepatitis (AIH). We performed a randomized, double-blind, placebo-controlled, prospective phase I clinical trial. Patients were adults with documented AIH with compensated chronic liver disease. Diagnosis of AIH was confirmed by either a pretreatment

Full Text available with Trip Pro

2018 Hepatology communications

19. Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report (PubMed)

Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report 30288473 2018 11 14 2471-254X 2 10 2018 Oct Hepatology communications Hepatol Commun Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report. 1179-1183 10.1002/hep4.1248 We report the case of a woman with chronic hepatitis C and idiopathic thrombocytopenic purpura (ITP) who developed autoimmune hepatitis (AIH) during antiviral therapy with ledipasvir (LDV)/sofosbuvir (SOF (...) ). The onset of acute hepatitis rose two weeks after starting treatment with LDV/SOF when HCV-RNA tested negative, suggesting a link between rapid HCV clearance and de novo autoimmune diseases. Conclusion: This case report proposes new immunologic scenarios in patients with hepatitis C virus (HCV) with laboratory or clinical signs of autoimmunity during direct-acting antiviral (DAA) therapy. Covini Giovanni G Liver Unit and Center for Autoimmune Liver Diseases. Bredi Elena E Clinical Investigation

Full Text available with Trip Pro

2018 Hepatology communications

20. Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta‐Analysis (PubMed)

Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta‐Analysis 30288470 2018 11 14 2471-254X 2 10 2018 Oct Hepatology communications Hepatol Commun Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis. 1160-1167 10.1002/hep4.1247 Successful treatment outcomes for chronic hepatitis B virus (HBV) infection requires high levels of adherence to treatment. We searched three (...) %). Reported barriers to adherence included forgetting, limited understanding of the importance of adherence, and change to routine. Conclusion : There is a need to reinforce assessment and reporting of adherence as a routine part of HBV care and to assess the extent to which evidence-based interventions to improve adherence to medication for human immunodeficiency virus [HIV] and other chronic diseases are effective for HBV infection. Ford Nathan N Department of HIV and Global Hepatitis Program World

Full Text available with Trip Pro

2018 Hepatology communications